RESERPINE ASCORBATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H40N2O9.C6H8O6
Molecular Weight	784.8028
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CO[C@H]2[C@@H](C[C@@H]3CN4CCC5=C(NC6=C5C=CC(OC)=C6)[C@H]4C[C@@H]3[C@@H]2C(=O)OC)OC(=O)C7=CC(OC)=C(OC)C(OC)=C7

InChI

InChIKey=WNJQGGIUASELQW-YDTMYOOKSA-N

InChI=1S/C33H40N2O9.C6H8O6/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19;7-1-2(8)5-3(9)4(10)6(11)12-5/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3;2,5,7-10H,1H2/t18-,22+,24-,27-,28+,31+;2-,5+/m10/s1

HIDE SMILES / InChI

Molecular Formula	C6H8O6
Molecular Weight	176.1241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C33H40N2O9
Molecular Weight	608.6787
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vesicular amine transporter 1 6 Target ID: CHEMBL1838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 555		160.0 nM [IC50]
Synaptic vesicular amine transporter 57 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 555		350.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Primary		Approved 8583	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date 1955
Agitated psychotic states 6 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Palliative		Approved 8583	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date 1955

C_max

Value	Dose	Co-administered	Analyte	Population
1.1 ng/mL OTHER https://www.drugs.com/pro/reserpine.html	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
200 h OTHER https://www.drugs.com/pro/reserpine.html	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
4.5 h DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b503fa5e-5726-426d-867c-e8fe59ed3ead&audience=consumer#page=3	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: POLYTHIAZIDE	POLYTHIAZIDE	RESERPINE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% OTHER https://www.drugs.com/pro/reserpine.html	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Upper abdominal pain, Postural hypotension... AEs leading to discontinuation/dose reduction: Upper abdominal pain (1 patient) Postural hypotension (1 patient) Electrocardiogram abnormal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Drowsiness, Light headedness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Light headedness (light, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

AEs

AE	Significance	Dose	Population
Electrocardiogram abnormal	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Postural hypotension	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Upper abdominal pain	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Drowsiness	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Light headedness	light, 1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years Health Status: unhealthy Age Group: 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 activator 150	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 BSEP 550 BCRP 910 MRP2 499 OATP1B1 1079 OATP1B3 961 OATP2B1 157 CYP1A2 2153 CYP2C19 2057 CYP2A6 879 CYP2E1 1060 Kv1.3 15 MRP3 246 MRP4 290	P-gp 2052	P-gp 301 CYP3A4/5 133

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	activator 342 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	no [Activation >3.9811 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	unlikely [Inhibition 20 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
Kv1.3 30	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706	weak [IC50 58 uM]
BSEP 554	inhibitor 4027 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/19520776/	yes [IC50 2.8 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11743742/, https://pubmed.ncbi.nlm.nih.gov/24396142/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	yes [IC50 20.4 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/, https://pubmed.ncbi.nlm.nih.gov/17430633/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50017712, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 26.3 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.03 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.2 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
OATP2B1 162	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
P-gp 1932	inhibitor 4027 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/10080959/, http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/12134945/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	yes [Ki 1.38 uM]
MRP2 625	inhibitor 4027 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/,https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/12134946/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.genome.jp/kegg/drug/br08309.html, https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [Ki 295 uM]
CYP3A4/5 357	inducer 1966 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes
P-gp 1932	inducer 1966 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706

PubMed

Title	Date	PubMed
Rat stomach ECL cells: mode of activation of histidine decarboxylase.	2003-06-15	12763636
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003-06	12711835
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.	2003-05-21	12748199
Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl.	2003-05	12754009
Osteology and skeletal development of Apalone spinifera (Reptilia: Testudines: Trionychidae).	2003-04	12616574
Studies on the long-term thermal stability of stationary phases in subcritical water chromatography.	2003-03-07	12641282
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.	2003-02-24	12592376
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.	2003-02-18	12587684
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.	2003-02-10	12569393
Optimization and validation of conventional and micellar LC methods for the analysis of methyltestosterone in sugar-coated pills.	2003-02-05	12560066
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.	2003-02-01	12576053
Expression of heart K+ channels in adrenalectomized and catecholamine-depleted reserpine-treated rats.	2003-02	12606256
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.	2003-02	12539206
The physiology of overwintering in a turtle that occupies multiple habitats, the common snapping turtle (Chelydra serpentina).	2003-01-17	12529844
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.	2003-01-14	12525265
Analysis of selected withanolides in plant extract by capillary electrochromatography and microemulsion electrokinetic chromatography.	2003-01	12569525
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.	2002-11-07	12408906
Determination of undecylenic and sorbic acids in cosmetic preparations by high performance liquid chromatography with electrochemical detection.	2002-11-07	12408884
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.	2002-10-04	12416886
A modified HPLC method for the determination of ochratoxin A by fluorescence detection.	2002-10	12378560
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.	2002-10	12235267
High-performance liquid chromatographic, capillary electrophoretic and capillary electrophoretic-electrospray ionisation mass spectrometric analysis of selected alkaloid groups.	2002-08-16	12219932
Augmentation of immune cell activity against tumor cells by Rauwolfia radix.	2002-08	12127238
Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.	2002-07-31	12093527
Validated HPLC method for determination of sennosides A and B in senna tablets.	2002-07-31	12093522
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.	2002-07-31	12093510
[Application of fingerprint chromatogram in quality control of Shen-Mai injection].	2002-07	12541909
Determination of L-sesamin and L-asarinin in Zanthoxylum(Roxb.) DC. by high performance liquid chromatography.	2002-07	12376305
Increase of free cysteine and citric acid in plant cells exposed to cobalt ions.	2002-07	12052512
Determination of ethylenediamine tetraacetic acid in injection forms by ion-pair chromatography.	2002-06-15	12049972
Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor.	2002-06	11933028
Validation of a simple liquid chromatographic method for determination and quantitation of residual ivermectin and doramectin in pig liver.	2002-05-07	11990020
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.	2002-05-01	11980384
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].	2002-05	12774329
[Determination of aspirin and free salicylic acid in lysinipirine injection by high performance liquid chromatography].	2002-05	12541957
Behavioral effects of MK-801 on reserpine-treated mice.	2002-04	11999899
Heterologous expression of a Rauvolfia cDNA encoding strictosidine glucosidase, a biosynthetic key to over 2000 monoterpenoid indole alkaloids.	2002-04	11985599
Simultaneous determination of N-oxides and free bases of pyrrolizidine alkaloids by cation-exchange solid-phase extraction and ion-pair high-performance liquid chromatography.	2002-03-08	11999741
[Determination of ofloxacin in human fallopian tube, uterus and serum by high performance liquid chromatography].	2002-02	12579960
Temperature effect on peak width and column efficiency in subcritical water chromatography.	2002-02	11881703
Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts.	2002	12189778
Identification of mammary carcinogens in rodent bioassays.	2002	11921183
[Determination of acyclovir in mouse plasma and tissues by reversed-phase high performance liquid chromatography].	2001-11	12545469
[Characterization and recognition key components in Astragalus membranaceus].	2001-07	12585085
[Determination of intestinal trefoil factor in burned rats by reversed-phase high performance liquid chromatography].	2001-07	12545493
[Determination of bifonazole in cream by high performance liquid chromatography].	2001-05	12541819
[Study of diphacinone in biological samples by high performance liquid chromatography/diode array detector].	2001-05	12541808
[Recognition and quantitative contrast characteristic components for root of Chinese angelica].	2001-03	12541663
[Behavior pharmacology of maprotiline, a new antidepressant].	1975-11	1240830
Effects of aminergic drugs and glutamic acid on audiogenic seizures induced by early exposure to ethanol.	1975-03	123503

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:08:01 GMT 2025` Edited by `admin` on `Mon Mar 31 23:08:01 GMT 2025`
Record UNII	D632O8555Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RESERPINE ASCORBATE

Common Name

English

L-ASCORBIC ACID, COMPD. WITH METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER)

Preferred Name

English

3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLIC ACID, 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY- METHYL ESTER 3,4,5-TRIMETHOXYBENZOATE (ESTER), L-ASCORBATE

Systematic Name

English

YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-, MONO-L-ASCORBATE

Systematic Name

English

RESERPINE, ASCORBATE

Common Name

English

Code System Code Type Description

PUBCHEM

92135773

Created by admin on Mon Mar 31 23:08:01 GMT 2025 , Edited by admin on Mon Mar 31 23:08:01 GMT 2025

PRIMARY

CAS

20235-11-4

Created by admin on Mon Mar 31 23:08:01 GMT 2025 , Edited by admin on Mon Mar 31 23:08:01 GMT 2025

NON-SPECIFIC STOICHIOMETRY

FDA UNII

D632O8555Z

Created by admin on Mon Mar 31 23:08:01 GMT 2025 , Edited by admin on Mon Mar 31 23:08:01 GMT 2025

PRIMARY

Related Record Type Details


					8B1QWR724A

RESERPINE

PARENT -> SALT/SOLVATE

Related Record Type Details


					8B1QWR724A

RESERPINE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

C_max

T_1/2

F_unbound

Drug as perpetrator